The Hepatic Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatic Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatic Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatic Injury and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Hepatic Injury by seven companies/universities/institutes. The top development phase for Hepatic Injury is preclinical with three drugs in that stage. The Hepatic Injury pipeline has five drugs in development by companies and two by universities/ institutes. Some of the companies in the Hepatic Injury pipeline products market are: Sanofi, Chonbuk National University School of Medicine and Elicio Therapeutics.
The key targets in the Hepatic Injury pipeline products market include Histone Deacetylase, DnaJ Homolog Subfamily C Member 15, and Cytochrome P450 3A4.
The key mechanisms of action in the Hepatic Injury pipeline product include Histone Deacetylase Inhibitor with one drug in Preclinical. The Hepatic Injury pipeline products include two routes of administration with the top ROA being Parenteral and two key molecule types in the Hepatic Injury pipeline products market including Small Molecule, and Cell Therapy.
Hepatic Injury overview
Hepatic injury, or liver trauma/injury, can occur from both penetrating and blunt abdominal injuries, including falls. The liver is the most injured organ in the human body. Liver traumas can range from minor lacerations or capsular hematomas to severe liver injuries with a high mortality rate. The frequency of liver injury could be due to its relatively fragile parenchyma and its fixed location below the diaphragm making it vulnerable to trauma. Diagnosis is done by physical and laboratory examination, or by administering IV contrast with CT scan to identify the extravasation of blood. Treatment is operative or nonoperative. Non-operative is chosen in hemodynamically stable patients, while the hemodynamically unstable are treated surgically.
For a complete picture of Hepatic Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
